AlexandraGatelyCornellMDMCR
Pediatric Pulmonology • Boston, MAChronic Lung Disease of Prematurity and Infancy, Cystic Fibrosis Pulmonology, Pediatric Asthma Pulmonology
Senior Medical Director, Merck Cardiovascular & Respiratory Clinical Research
Dr. Cornell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
33 Avenue Louis Pasteur
Boston, MA 02115
Education & Training
OHSUMCR, Clinical Research, 2013 - 2018- NYP Hosp-Columbia Univ Med Ctr2011
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Pediatrics, 2005 - 2008- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalInternship, Pediatrics, 2005 - 2006
University of Vermont College of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2019 - 2026
OR State Medical License 2013 - 2021
NH State Medical License Active through 2013
NY State Medical License 2008 - 2012- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Pulmonology
Clinical Trials
- Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2013 Jul 01
- OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis Start of enrollment: 2014 Jun 01
- Saline Hypertonic in Preschoolers Start of enrollment: 2015 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsLong-term safety and efficacy of lumacaftor/ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, ope...Mark A. Chilvers, Jane C. Davies, Carlos Milla, S. Tian, Zifei Han
The Lancet. Respiratory Medicine. 2021-07-01 - 23 citationsLong-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, ...Jordana E. Hoppe, Mark A. Chilvers, Felix Ratjen, John McNamara, Caroline A. Owen
The Lancet. Respiratory Medicine. 2021-05-06 - 78 citationsInhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trialFelix Ratjen, Stephanie D. Davis, Sanja Stanojevic, Richard A. Kronmal, Karen Hinckley Stukovsky
The Lancet. Respiratory Medicine. 2019-09-01
Journal Articles
- Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, ope...Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F, Lancet Respiratory Medicine, 1/28/2021
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
